Recro Pharma (REPH) Stock Price, News & Analysis

Company Overview

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.47 to $2.11
• 52-Week Range: N/A
• Volume: 141,800 shs
• Average Volume: 126,298 shs
• Market Capitalization: $117.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Recro Pharma Stock Analysis - MarketRank™

Recro Pharma scored higher than 18% of companies evaluated by MarketBeat, and ranked 859th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Recro Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Recro Pharma are expected to grow in the coming year, from ($0.21) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Recro Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Recro Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for REPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Recro Pharma does not currently pay a dividend.

Dividend Growth

Recro Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -1.12

Short Interest

There is no current short interest data available for REPH.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for REPH on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Recro Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.20% of the stock of Recro Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.34% of the stock of Recro Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

REPH Stock Analysis - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) issued its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%.

What other stocks do shareholders of Recro Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 3/01/2022
• Today: 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:REPH
• CIK: 1588972
• Web: www.recropharma.com
• Phone: (770) 534-8239
• Fax: 484-395-2471
• Employees: 185
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.37 million
• Net Margins: -15.15%
• Pretax Margin: -15.09%
• Return on Equity: -56.66%
• Return on Assets: -11.14%

Debt

• Debt-to-Equity Ratio: 2.27
• Current Ratio: 3.24
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $75.36 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 56,424,000
• Free Float: 48,412,000
• Market Cap: $117.93 million
• Optionable: Optionable
• Beta: 1.08